Hepatocyte targeting using pegylated asialofetuin-conjugated liposomes

References

• Poelstra K, Prakash J, Beljaars L. Drug targeting to the diseased liver. J Control Release 2012;161:188–97
   PubMed Web of Science ®Google Scholar
• Casey LC, Lee WM. Hepatitis C therapy update. Curr Opin Gastroenterol 2012;28:188–92
   PubMed Web of Science ®Google Scholar
• Lampertico P, Liaw YF. New perspectives in the therapy of chronic hepatitis B. Gut 2012;61 Suppl 1:i18–24
   PubMed Web of Science ®Google Scholar
• Siebler J, Galle PR. Treatment of nonalcoholic fatty liver disease. World J Gastroenterol 2006;12:2161–7
   PubMed Web of Science ®Google Scholar
• Aravalli RN, Cressman ENK, Steer CJ. Cellular and molecular mechanisms of hepatocellular carcinoma: an update. Arch Toxicol 2013;87:227–47
   PubMed Web of Science ®Google Scholar
• Huwyler J, Drewe J, Krähenbuhl S. Tumor targeting using liposomal antineoplastic drugs. Int J Nanomed 2008;3:21–9
   PubMed Web of Science ®Google Scholar
• Milla P, Dosio F, Cattel L. PE Gylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery. Curr Drug Metab 2012;13:105–19
   PubMed Web of Science ®Google Scholar
• Halm U, Etzrodt G, Schiefke I, et al. A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma. Ann Oncol 2000;11:113–14
   PubMed Web of Science ®Google Scholar
• Janssen HLA, Reesink HW, Lawitz EJ, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013;368:1685–94
   PubMed Web of Science ®Google Scholar
• Schwartz AL. The hepatic asialoglycoprotein receptor. CRC Crit Rev Biochem 1984;16:207–33
   PubMed Web of Science ®Google Scholar
• Stockert RJ. The asialoglycoprotein receptor: relationships between structure, function, and expression. Physiol Rev 1995;75:591–609
   PubMed Web of Science ®Google Scholar
• Wu J, Nantz MH, Zern MA. Targeting hepatocytes for drug and gene delivery: emerging novel approaches and applications. Front Biosci 2002;7:d717–25
   PubMed Web of Science ®Google Scholar
• Managit C, Kawakami S, Nishikawa M, et al. Targeted and sustained drug delivery using PEGylated galactosylated liposomes. Int J Pharm 2003;266:77–84
   PubMed Web of Science ®Google Scholar
• Shimada K, Kamps JA, Regts J, et al. Biodistribution of liposomes containing synthetic galactose-terminated diacylglyceryl-poly(ethyleneglycol)s. Biochim Biophys Acta 1997;1326:329–41
   PubMed Web of Science ®Google Scholar
• Wang S, Xu H, Xu J, et al. Sustained liver targeting and improved antiproliferative effect of doxorubicin liposomes modified with galactosylated lipid and PEG-lipid. AAPS PharmSciTech 2010;11:870–7
   PubMed Web of Science ®Google Scholar
• Connolly DT, Townsend RR, Kawaguchi K, et al. Binding and endocytosis of cluster glycosides by rabbit hepatocytes. Evidence for a short-circuit pathway that does not lead to degradation. J Biol Chem 1982;257:939–45
   Google Scholar
• Neue K, Mormann M, Peter-Katalinić J, Pohlentz G. Elucidation of glycoprotein structures by unspecific proteolysis and direct nanoESI mass spectrometric analysis of ZIC-HILIC-enriched glycopeptides. J Proteome Res 2011;10:2248–60
   PubMed Web of Science ®Google Scholar
• Dasí F, Benet M, Crespo J, et al. Asialofetuin liposome-mediated human alpha1-antitrypsin gene transfer in vivo results in stationary long-term gene expression. J Mol Med 2001;79:205–12
   PubMed Web of Science ®Google Scholar
• Gregoriadis G, Neerunjun ED. Homing of liposomes to target cells. Biochem Biophys Res Commun 1975;65:537–44
   PubMed Web of Science ®Google Scholar
• Hara T, Aramaki Y, Tsuchiya S, et al. Specific incorporation of asialofetuin-labeled liposomes into hepatocytes through the action of galactose-binding protein. Biopharm Drug Dispos 1987;8:327–39
   PubMed Web of Science ®Google Scholar
• Hara T, Ishihara H, Aramaki Y, Tsuchiya S. Specific uptake of asialofetuin-labeled liposomes by isolated hepatocytes. Int J Pharm 1988;42:69–75
   Google Scholar
• Tros de Ilarduya C. Serum-resistant lipoplexes in the presence of asialofetuin. Methods Mol Biol 2010;605:425–34
   PubMedGoogle Scholar
• Huwyler J, Wu D, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA 1996;93:14164–9
   PubMed Web of Science ®Google Scholar
• Stewart JC. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem 1980;104:10–14
   PubMed Web of Science ®Google Scholar
• Kettiger H, Schipanski A, Wick P, Huwyler J. Engineered nanomaterial uptake and tissue distribution: from cell to organism. Int J Nanomedicine 2013;8:3255–69
   PubMed Web of Science ®Google Scholar
• Garbuzenko O, Barenholz Y, Priev A. Effect of grafted PEG on liposome size and on compressibility and packing of lipid bilayer. Chem Phys Lipids 2005;135:117–29
   PubMed Web of Science ®Google Scholar
• Hansen CB, Kao GY, Moase EH, et al. Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim Biophys Acta 1995;1239:133–44
   PubMed Web of Science ®Google Scholar
• Cowper KB, Currin RT, Dawson TL, et al. A new method to monitor Kupffer-cell function continuously in the perfused rat liver. Dissociation of glycogenolysis from particle phagocytosis. Biochem J 1990;266:141–7
   Google Scholar
• Allen TM, Hansen CB. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim Biophys Acta 1991;1068:133–41
   PubMed Web of Science ®Google Scholar
• Managit C, Kawakami S, Yamashita F, Hashida M. Uptake characteristics of galactosylated emulsion by HepG2 hepatoma cells. Int J Pharm 2005;301:255–61
   PubMed Web of Science ®Google Scholar
• Pathak A, Vyas SP, Gupta KC. Nano-vectors for efficient liver specific gene transfer. Int J Nanomed 2008;3:31–49
   PubMed Web of Science ®Google Scholar
• Tolleshaug H, Berg T, Nilsson M, Norum KR. Uptake and degradation of 125I-labelled asialo-fetuin by isolated rat hepatocytes. Biochim Biophys Acta 1977;499:73–84
   PubMed Web of Science ®Google Scholar
• Rice KG, Rao NB, Lee YC. Large-scale preparation and characterization of N-linked glycopeptides from bovine fetuin. Anal Biochem 1990;184:249–58
   PubMed Web of Science ®Google Scholar
• Murao A, Nishikawa M, Managit C, et al. Targeting efficiency of galactosylated liposomes to hepatocytes in vivo: effect of lipid composition. Pharm Res 2002;19:1808–14
   PubMed Web of Science ®Google Scholar
• Wu X, Liu H, Liu J, et al. Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nat Biotechnol 2003;21:41–6
   PubMed Web of Science ®Google Scholar
• Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates for imaging, labelling and sensing. Nat Mater 2005;4:435–46
   PubMed Web of Science ®Google Scholar
• Michalet X, Pinaud FF, Bentolila LA, et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science 2005;307:538–44
   PubMed Web of Science ®Google Scholar
• Generalov R, Kavaliauskiene S, Westrøm S, et al. Entrapment in phospholipid vesicles quenches photoactivity of quantum dots. Int J Nanomed 2011;6:1875–88
   PubMed Web of Science ®Google Scholar
• Morell AG, Gregoriadis G, Scheinberg IH, et al. The role of sialic acid in determining the survival of glycoproteins in the circulation. J Biol Chem 1971;246:1461–7
   PubMed Web of Science ®Google Scholar
• Neyrinck AM, De Wispelaere LD, Vanhulle VP, et al. Are Kupffer cells involved in the metabolic adaptation of the liver to dietary carbohydrates given after fasting? Biochim Biophys Acta 2000;1475:238–44
   PubMed Web of Science ®Google Scholar
• Nilsson B, Svensson S. A new method for degradation of the protein part of glycoproteins: isolation of the carbohydrate chains of asialofetuin. Carbohydr Res 1979;72:183–90
   PubMed Web of Science ®Google Scholar
• Stokmaier D, Khorev O, Cutting B, et al. Design, synthesis and evaluation of monovalent ligands for the asialoglycoprotein receptor (ASGP-R). Bioorg Med Chem 2009;17:7254–64
   PubMed Web of Science ®Google Scholar